1258453-75-6

Basic information

• Product Name: ABX-464
• Synonyms: ABX-464
• CAS NO: 1258453-75-6
• Molecular Formula: C₁₆H₁₀ClF₃N₂O
• Molecular Weight: 338.7116096
• EINECS: -0
• Mol File: 1258453-75-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 412.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.440±0.06 g/cm3(Predicted)
• PKA: 1.50±0.61(Predicted)
• CAS DataBase Reference: ABX-464(CAS DataBase Reference)
• NIST Chemistry Reference: ABX-464(1258453-75-6)
• EPA Substance Registry System: ABX-464(1258453-75-6)

Safety Data

• Hazardous Substances Data: 1258453-75-6(Hazardous Substances Data)

Usage

General Description

ABX-464 is a novel chemical compound that has shown promise in treating inflammatory and autoimmune diseases. It works by targeting a specific protein, leading to the suppression of inflammatory responses within the body. In preclinical studies, ABX-464 has demonstrated anti-inflammatory and tissue protective effects in various experimental models, showing potential as a treatment for conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, and inflammatory bowel disease. Additionally, it has been found to have a favorable safety and tolerability profile in early clinical trials, making it a promising candidate for further development as a therapeutic agent.

Upstream product

• 4470-83-1 2,8-dichloroquinoline 
• 461-82-5 4-(trifluoromethoxy)aniline 

Relevant articles and documents

Solvent-free mechanochemical Buchwald-Hartwig amination of aryl chlorides without inert gas protection

A solvent-free Buchwald-Hartwig amination had been developed under high-speed ball-milling conditions, which afforded the desired products with moderate to high yields. The addition of sodium sulfate was found to be crucial for improving both the performance and the reproducibility. Comparative solvent-free stirring experiments implicated the importance of mechanical interaction for the transformation, and the inert gas was proved to be unnecessary for this amination.

BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES

Described herein are methods for preventing or treating a retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection. In certain aspects, the methods described herein include contacting a cell in need thereof with compound (I), wherein (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a –CN group, a hydroxyl group, a –COOR1 group, a (C1 -C3)fluoroalkyl group, a (C1 -C3)fluoroalkoxy group, a –NO2 group, a –NR1R2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n' is 1 or 2, R' is a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group,, a hydroxyl group, a –COOR1 group, a –NO2 group, a –NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a –CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, to prevent or treat the retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection, wherein the retroviral infection is not HIV and the disease caused by the retroviral infection is not AIDS.